Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors

Sym004 is a 1:1 mixture of two antibodies targeting non‐overlapping epitopes of the epidermal growth factor receptor that antagonizes ligand binding and induces receptor downregulation. In preclinical models, it has superior antitumor activity to cetuximab and panitumumab. Japanese adults aged ≥20 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Kojima, Takashi, Yamazaki, Kentaro, Kato, Ken, Muro, Kei, Hara, Hiroki, Chin, Keisho, Goddemeier, Thomas, Kuffel, Stefan, Watanabe, Morihiro, Doi, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172077/
https://www.ncbi.nlm.nih.gov/pubmed/30099818
http://dx.doi.org/10.1111/cas.13767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172077/
https://www.ncbi.nlm.nih.gov/pubmed/30099818
http://dx.doi.org/10.1111/cas.13767

Ejemplares similares